0001390478-24-000006.txt : 20240329 0001390478-24-000006.hdr.sgml : 20240329 20240329160045 ACCESSION NUMBER: 0001390478-24-000006 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20240329 DATE AS OF CHANGE: 20240329 EFFECTIVENESS DATE: 20240329 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SELLAS Life Sciences Group, Inc. CENTRAL INDEX KEY: 0001390478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-509138 FILM NUMBER: 24804076 BUSINESS ADDRESS: STREET 1: 7 TIMES SQUARE STREET 2: SUITE 2503 CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 6462005278 MAIL ADDRESS: STREET 1: 7 TIMES SQUARE STREET 2: SUITE 2503 CITY: NEW YORK STATE: NY ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: Galena Biopharma, Inc. DATE OF NAME CHANGE: 20110926 FORMER COMPANY: FORMER CONFORMED NAME: RXi Pharmaceuticals Corp DATE OF NAME CHANGE: 20110926 FORMER COMPANY: FORMER CONFORMED NAME: GALENA BIOPHARMA, INC. DATE OF NAME CHANGE: 20110922 D 1 primary_doc.xml X0708 D LIVE 0001390478 SELLAS Life Sciences Group, Inc. 7 TIMES SQUARE SUITE 2503 NEW YORK NY NEW YORK 10036 6462005278 DELAWARE Galena Biopharma, Inc. RXi Pharmaceuticals Corp GALENA BIOPHARMA, INC. Corporation true Angelos M. Stergiou 7 Times Square Suite 2503 New York NY NEW YORK 10036 Executive Officer Director John T. Burns 7 Times Square Suite 2503 New York NY NEW YORK 10036 Executive Officer Katherine Bach Kalin 7 Times Square Suite 2503 New York NY NEW YORK 10036 Director David A. Scheinberg 7 Times Square Suite 2503 New York NY NEW YORK 10036 Director Robert Van Nostrand 7 Times Square Suite 2503 New York NY NEW YORK 10036 Director John Varian 7 Times Square Suite 2503 New York NY NEW YORK 10036 Director Jane Wasman 7 Times Square Suite 2503 New York NY NEW YORK 10036 Director Biotechnology Decline to Disclose 06b false 2024-03-15 false true true false 0 A.G.P./Alliance Global Partners 8361 None None 590 Madison Avenue 28th Floor New York NY NEW YORK 10022 All States true 18371336 18371336 0 Represents the aggregate exercise price of warrants for 13,029,316 shares of common stock issued in connection with a registered direct offering of 11,000,000 shares of common stock and 2,029,316 pre-funded warrants. false 4 1399985 60000 $1,399,985.80 is for a fee of 7.0% of the gross proceeds from the sale of securities in the registered direct offering and concurrent private placement of warrants, and up to $60,000 is for the reimbursement of expenses incurred by the placement agent. 0 false SELLAS Life Sciences Group, Inc. /s/John T. Burns John T. Burns CFO 2024-03-29